<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1.0" />
  <title>The Complete Guide to Resistance Training on GLP-1 Medication – Élan Clinic</title>
  <meta name="description" content="Up to 39% of weight lost on semaglutide is lean mass. A physician explains why resistance training is essential on GLP-1 therapy — and exactly how to structure it." />
  <link rel="canonical" href="https://elan.clinic/blog/resistance-training-on-glp1.html" />
  <link rel="icon" type="image/svg+xml" href="/favicon.svg" />

  <!-- Open Graph -->
  <meta property="og:type" content="article" />
  <meta property="og:url" content="https://elan.clinic/blog/resistance-training-on-glp1.html" />
  <meta property="og:title" content="The Complete Guide to Resistance Training on GLP-1 Medication" />
  <meta property="og:description" content="Up to 39% of weight lost on semaglutide is lean mass. A physician explains why resistance training is essential on GLP-1 therapy — and exactly how to structure it." />
  <meta property="og:locale" content="en_GB" />
  <meta property="article:published_time" content="2026-03-01" />
  <meta property="article:author" content="Dr. Ingmar Lindström" />

  <!-- Schema.org MedicalWebPage -->
  <script type="application/ld+json">
  {
    "@context": "https://schema.org",
    "@type": "MedicalWebPage",
    "name": "The Complete Guide to Resistance Training on GLP-1 Medication",
    "headline": "The Complete Guide to Resistance Training on GLP-1 Medication",
    "url": "https://elan.clinic/blog/resistance-training-on-glp1.html",
    "datePublished": "2026-03-01",
    "inLanguage": "en",
    "description": "Up to 39% of weight lost on semaglutide is lean mass. A physician explains why resistance training is essential on GLP-1 therapy — and exactly how to structure it.",
    "about": {
      "@type": "MedicalCondition",
      "name": "Obesity"
    },
    "medicalAudience": {
      "@type": "MedicalAudience",
      "audienceType": "Patient"
    },
    "author": {
      "@type": "Person",
      "name": "Dr. Ingmar Lindström",
      "jobTitle": "Physician",
      "worksFor": {
        "@type": "MedicalClinic",
        "name": "Élan Clinic",
        "url": "https://elan.clinic"
      }
    },
    "publisher": {
      "@type": "MedicalClinic",
      "name": "Élan Clinic",
      "url": "https://elan.clinic",
      "logo": "https://elan.clinic/favicon.svg",
      "telephone": "+37252999399",
      "address": {
        "@type": "PostalAddress",
        "streetAddress": "Sepapaja 12/1",
        "addressLocality": "Tallinn",
        "postalCode": "11415",
        "addressCountry": "EE"
      }
    },
    "mainEntityOfPage": {
      "@type": "WebPage",
      "@id": "https://elan.clinic/blog/resistance-training-on-glp1.html"
    },
    "citation": [
      {
        "@type": "ScholarlyArticle",
        "name": "STEP 1 DXA sub-study: body composition changes with semaglutide 2.4 mg",
        "isPartOf": { "@type": "Periodical", "name": "New England Journal of Medicine" },
        "datePublished": "2021"
      },
      {
        "@type": "ScholarlyArticle",
        "name": "Longland et al. Higher compared with lower dietary protein during an energy deficit combined with intense exercise promotes greater lean mass gain",
        "isPartOf": { "@type": "Periodical", "name": "American Journal of Clinical Nutrition" },
        "datePublished": "2016"
      },
      {
        "@type": "ScholarlyArticle",
        "name": "Morton et al. A systematic review, meta-analysis and meta-regression of the effect of protein supplementation on resistance training-induced gains in muscle mass and strength in healthy adults",
        "isPartOf": { "@type": "Periodical", "name": "British Journal of Sports Medicine" },
        "datePublished": "2018"
      }
    ]
  }
  </script>

  <!-- Google Fonts -->
  <link rel="preconnect" href="https://fonts.googleapis.com" />
  <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin />
  <link href="https://fonts.googleapis.com/css2?family=Playfair+Display:ital,wght@0,400;0,500;0,600;0,700;1,400;1,500&family=Inter:wght@300;400;500;600&display=swap" rel="stylesheet" />

  <style>
    *, *::before, *::after { box-sizing: border-box; margin: 0; padding: 0; }
    html { scroll-behavior: smooth; font-size: 16px; }
    body {
      font-family: 'Inter', sans-serif;
      background-color: #0D1B2A;
      color: rgba(232, 228, 222, 0.55);
      line-height: 1.7;
      -webkit-font-smoothing: antialiased;
    }
    h1, h2, h3, h4 { font-family: 'Playfair Display', serif; color: #E8E4DE; line-height: 1.2; font-weight: 500; }
    a { color: #C5A55A; text-decoration: none; }
    a:hover { text-decoration: underline; }
    .container { width: 100%; max-width: 1200px; margin: 0 auto; padding: 0 24px; }
    .label { display: inline-block; font-family: 'Inter', sans-serif; font-size: 0.7rem; font-weight: 600; letter-spacing: 0.18em; text-transform: uppercase; color: #C5A55A; margin-bottom: 20px; }
    .gold-line { width: 48px; height: 2px; background: #C5A55A; margin: 28px 0; }
    .nav { position: fixed; top: 0; left: 0; right: 0; z-index: 100; padding: 20px 24px; display: flex; align-items: center; justify-content: space-between; background: rgba(13, 27, 42, 0.92); backdrop-filter: blur(12px); border-bottom: 1px solid rgba(197, 165, 90, 0.12); }
    .nav__logo { font-family: 'Playfair Display', serif; font-size: 1.25rem; color: #E8E4DE; letter-spacing: 0.06em; text-decoration: none; }
    .nav__logo span { color: #C5A55A; }
    .nav__links { display: flex; align-items: center; gap: 32px; list-style: none; }
    .nav__links a { font-size: 0.78rem; font-weight: 500; letter-spacing: 0.1em; text-transform: uppercase; color: rgba(232, 228, 222, 0.65); text-decoration: none; transition: color 0.2s; }
    .nav__links a:hover, .nav__links a.active { color: #C5A55A; }
    .breadcrumb { padding: 120px 0 0; background-color: #0D1B2A; }
    .breadcrumb__inner { display: flex; align-items: center; gap: 8px; flex-wrap: wrap; }
    .breadcrumb__item { font-size: 0.75rem; font-weight: 500; letter-spacing: 0.08em; color: rgba(232, 228, 222, 0.4); text-transform: uppercase; }
    .breadcrumb__item a { color: rgba(232, 228, 222, 0.4); text-decoration: none; transition: color 0.2s; }
    .breadcrumb__item a:hover { color: #C5A55A; text-decoration: none; }
    .breadcrumb__sep { font-size: 0.7rem; color: rgba(197, 165, 90, 0.4); }
    .breadcrumb__item--current { color: #C5A55A; }
    .article-header { padding: 48px 0 64px; background-color: #0D1B2A; position: relative; overflow: hidden; }
    .article-header::before { content: ''; position: absolute; top: -100px; right: -150px; width: 500px; height: 500px; background: radial-gradient(circle, rgba(197,165,90,0.05) 0%, transparent 70%); pointer-events: none; }
    .article-header__content { max-width: 780px; }
    .article-header h1 { font-size: clamp(2rem, 4.5vw, 3.2rem); line-height: 1.15; margin-bottom: 28px; }
    .article-meta { display: flex; align-items: center; flex-wrap: wrap; gap: 24px; padding-top: 24px; border-top: 1px solid rgba(197, 165, 90, 0.15); }
    .article-meta__item { display: flex; align-items: center; gap: 8px; font-size: 0.8rem; color: rgba(232, 228, 222, 0.5); }
    .article-meta__item strong { color: rgba(232, 228, 222, 0.75); font-weight: 500; }
    .article-meta__dot { width: 3px; height: 3px; border-radius: 50%; background: rgba(197, 165, 90, 0.4); }
    .article-body { padding: 0 0 100px; background-color: #0D1B2A; }
    .article-body__inner { max-width: 780px; }
    .article-body p { font-size: 1.05rem; color: rgba(232, 228, 222, 0.72); line-height: 1.85; margin-bottom: 28px; }
    .article-body h2 { font-size: clamp(1.5rem, 2.5vw, 2rem); margin: 56px 0 20px; color: #E8E4DE; }
    .article-body h3 { font-size: clamp(1.1rem, 2vw, 1.35rem); margin: 40px 0 16px; color: #E8E4DE; }
    .article-body strong { color: rgba(232, 228, 222, 0.9); font-weight: 600; }
    .article-body em { color: rgba(232, 228, 222, 0.65); font-style: italic; }
    .article-body hr { border: none; height: 1px; background: rgba(197, 165, 90, 0.15); margin: 48px 0; }
    .pull-quote { border-left: 3px solid #C5A55A; padding: 20px 32px; margin: 40px 0; background: rgba(197, 165, 90, 0.04); }
    .pull-quote p { font-family: 'Playfair Display', serif; font-size: 1.2rem !important; font-style: italic; color: rgba(232, 228, 222, 0.82) !important; line-height: 1.6 !important; margin: 0 !important; }
    .key-stat { background: #111D2E; border: 1px solid rgba(197, 165, 90, 0.18); padding: 32px 36px; margin: 40px 0; }
    .key-stat__number { font-family: 'Playfair Display', serif; font-size: 3rem; color: #C5A55A; line-height: 1; margin-bottom: 8px; }
    .key-stat__label { font-size: 0.88rem; color: rgba(232, 228, 222, 0.6); line-height: 1.5; }
    .article-sources { margin-top: 60px; padding-top: 32px; border-top: 1px solid rgba(197, 165, 90, 0.12); }
    .article-sources p { font-size: 0.82rem !important; color: rgba(232, 228, 222, 0.38) !important; line-height: 1.6 !important; margin-bottom: 8px !important; }
    .article-sources .sources-label { font-size: 0.7rem; font-weight: 600; letter-spacing: 0.15em; text-transform: uppercase; color: #C5A55A; margin-bottom: 16px; display: block; }
    .back-link { display: inline-flex; align-items: center; gap: 8px; font-size: 0.78rem; font-weight: 600; letter-spacing: 0.1em; text-transform: uppercase; color: rgba(232, 228, 222, 0.5); text-decoration: none; transition: color 0.2s, gap 0.2s; margin-bottom: 60px; }
    .back-link:hover { color: #C5A55A; gap: 12px; text-decoration: none; }
    .footer-cta { background-color: #111D2E; border-top: 1px solid rgba(197, 165, 90, 0.12); text-align: center; padding: 100px 24px; }
    .footer-cta h2 { max-width: 620px; margin: 0 auto 24px; font-size: clamp(1.6rem, 3vw, 2.2rem); }
    .footer-cta__sub { max-width: 480px; margin: 0 auto 40px; font-size: 0.95rem; }
    .btn { display: inline-block; padding: 16px 36px; font-family: 'Inter', sans-serif; font-size: 0.85rem; font-weight: 600; letter-spacing: 0.1em; text-transform: uppercase; border: 1.5px solid #C5A55A; color: #C5A55A; background: transparent; cursor: pointer; transition: background 0.2s, color 0.2s; text-decoration: none; }
    .btn:hover { background: #C5A55A; color: #0D1B2A; text-decoration: none; }
    .btn--filled { background: #C5A55A; color: #0D1B2A; }
    .btn--filled:hover { background: #d4b56a; color: #0D1B2A; }
    .footer-legal { background-color: #0D1B2A; border-top: 1px solid rgba(197, 165, 90, 0.08); padding: 40px 24px; }
    .footer-legal__inner { max-width: 1200px; margin: 0 auto; display: flex; flex-direction: column; gap: 8px; }
    .footer-legal p { font-size: 0.75rem; color: rgba(232, 228, 222, 0.3); line-height: 1.6; }
    @media (max-width: 768px) {
      .nav__links { gap: 16px; }
      .nav__links a { font-size: 0.72rem; }
      .breadcrumb { padding-top: 100px; }
      .article-header { padding: 32px 0 48px; }
      .article-body p { font-size: 0.98rem; }
      .key-stat__number { font-size: 2.4rem; }
      .pull-quote { padding: 16px 20px; }
    }
  </style>
</head>
<body>

  <!-- ═══ Navigation ══════════════════════════════════════════════════════ -->
  <nav class="nav">
    <a href="/" class="nav__logo">Élan<span>.</span></a>
    <ul class="nav__links">
      <li><a href="/">Home</a></li>
      <li><a href="/blog.html" class="active">Articles</a></li>
      <li><a href="/faq.html">FAQ</a></li>
      <li style="margin-left:8px;border-left:1px solid rgba(197,165,90,0.25);padding-left:16px;display:flex;gap:12px;"><a href="/et.html" style="font-size:0.7rem;">EST</a> <a href="/ukk.html" style="font-size:0.7rem;">FIN</a> <a href="/voprosy.html" style="font-size:0.7rem;">RUS</a></li>
      <li><a href="/#consultation" class="btn" style="padding: 10px 20px; font-size: 0.72rem;">Book a Consultation</a></li>
    </ul>
  </nav>

  <!-- ═══ Breadcrumb ══════════════════════════════════════════════════════ -->
  <div class="breadcrumb">
    <div class="container">
      <nav class="breadcrumb__inner" aria-label="Breadcrumb">
        <span class="breadcrumb__item"><a href="/">Home</a></span>
        <span class="breadcrumb__sep">›</span>
        <span class="breadcrumb__item"><a href="/blog.html">Articles</a></span>
        <span class="breadcrumb__sep">›</span>
        <span class="breadcrumb__item breadcrumb__item--current">Resistance Training on GLP-1</span>
      </nav>
    </div>
  </div>

  <!-- ═══ Article Header ══════════════════════════════════════════════════ -->
  <header class="article-header">
    <div class="container">
      <div class="article-header__content">
        <span class="label">GLP-1 Medications · Exercise &amp; Body Composition</span>
        <h1>The Complete Guide to Resistance Training on GLP-1 Medication</h1>
        <div class="article-meta">
          <div class="article-meta__item">
            <strong>Dr. Ingmar Lindström</strong>
          </div>
          <div class="article-meta__dot"></div>
          <div class="article-meta__item">
            <time datetime="2026-03-01">March 1, 2026</time>
          </div>
          <div class="article-meta__dot"></div>
          <div class="article-meta__item">
            12 min read
          </div>
        </div>
      </div>
    </div>
  </header>

  <!-- ═══ Article Body ═════════════════════════════════════════════════════ -->
  <main class="article-body">
    <div class="container">
      <div class="article-body__inner">

        <div class="pull-quote">
          <p>"We are what we repeatedly do. Excellence, then, is not an act but a habit." — Aristotle</p>
        </div>

        <p>
          Aristotle was describing virtue, but he could have been writing a prescription for body composition management. The things you do consistently — not occasionally, not heroically once — determine what your body looks like and how it functions. And for people on GLP-1 medication, what you do repeatedly in the gym, or don't do, will determine whether the weight you lose is fat or something considerably more valuable.
        </p>

        <p>
          The STEP 1 DXA sub-study changed how I talk to people about GLP-1 therapy. It gave us, for the first time, a rigorous body composition picture of what happens when you lose significant weight on semaglutide without a structured resistance training programme. The numbers are important enough to lead with.
        </p>

        <hr />

        <h2>The Problem: What's Actually Being Lost</h2>

        <p>
          In the STEP 1 DXA sub-study, 140 participants underwent dual-energy X-ray absorptiometry (DXA) — the gold standard for body composition measurement — at baseline and at the end of 68 weeks of semaglutide 2.4 mg therapy. The results were illuminating and, for the field, somewhat sobering.
        </p>

        <div class="key-stat">
          <div class="key-stat__number">39%</div>
          <div class="key-stat__label">Proportion of total weight lost on semaglutide that was lean mass in the STEP 1 DXA sub-study (n=140) — meaning roughly 4 kg of lean tissue lost for every 10 kg of total weight reduction, without a structured resistance training programme.</div>
        </div>

        <p>
          Of the total weight lost, approximately <strong>39% was lean mass</strong> — not fat. That means for every 10 kilograms lost, roughly 4 kilograms came from muscle, bone density, organ tissue, and structural protein rather than from adipose tissue. Overall fat mass fell by 19.3% and lean body mass fell by 9.7%.
        </p>

        <p>
          To put that in clinical context: a person starting at 100 kg who loses 15 kg on semaglutide without structured resistance training might lose approximately 9 kg of fat and 6 kg of lean mass. That lean mass loss includes skeletal muscle — the tissue that drives metabolic rate, protects joints, maintains function, and makes the difference between a body that's lighter and a body that's stronger.
        </p>

        <p>
          Lean mass loss at this scale has real consequences beyond the numbers. It lowers resting metabolic rate, which increases the likelihood of weight regain after stopping medication. It reduces strength and functional capacity. And it accelerates sarcopenic processes that, in older adults, are directly linked to disability and mortality risk.
        </p>

        <p>
          This is not a reason not to use GLP-1 therapy. It is a reason to use it differently — with resistance training as a mandatory co-intervention, not an optional add-on.
        </p>

        <hr />

        <h2>Why Resistance Training Changes the Equation</h2>

        <p>
          The mechanism is well-established: resistance exercise creates a mechanical stimulus that drives myofibrillar protein synthesis — the production of contractile muscle proteins — through mechanotransduction pathways including mTOR activation. When combined with adequate dietary protein, this stimulus can not only preserve lean mass during a caloric deficit but, in some cases, increase it.
        </p>

        <p>
          Longland et al. (2016) demonstrated this in a landmark study of 40 young men in a significant caloric deficit (–40% of maintenance calories). Participants randomised to higher protein intake (2.4 g/kg/day) and resistance training actually gained lean mass (+1.2 kg) while losing fat (–4.8 kg) — a simultaneous body recomposition in a deficit so severe that it would be unsustainable long-term. The key variable was not the deficit itself, but the combination of training stimulus and adequate protein supply.
        </p>

        <p>
          Morton et al. (2018) conducted the definitive meta-analysis of protein supplementation on resistance training outcomes — 49 randomised trials, 1,863 participants. The finding relevant here: protein beyond 1.62 g/kg/day produced no additional lean mass gain, but below that threshold, outcomes were substantially worse. The ceiling and floor for protein are established. Work within them, and resistance training reliably drives lean mass preservation or gain regardless of caloric status.
        </p>

        <p>
          For people on GLP-1 therapy — who are typically in a significant appetite-suppressed caloric deficit — resistance training combined with targeted protein intake is the intervention that shifts the body composition outcome from "weight loss including muscle" to "fat loss with muscle preservation."
        </p>

        <hr />

        <h2>How Much Training Is Enough?</h2>

        <p>
          The evidence supports a minimum effective dose of <strong>two to three resistance training sessions per week</strong>, each targeting major muscle groups through compound movements. More is better, up to a point — but the marginal benefit beyond four sessions per week diminishes, and recovery becomes a limiting factor, particularly during caloric restriction when muscle protein synthesis is already somewhat blunted.
        </p>

        <h3>The minimum effective programme</h3>

        <p>
          <strong>Frequency:</strong> 3 sessions per week. Sessions of 45–60 minutes are sufficient. More time does not linearly produce more results; adequate intensity and progressive load do.
        </p>

        <p>
          <strong>Exercise selection:</strong> Prioritise compound movements — exercises that train multiple muscle groups simultaneously. Squat, deadlift, hip hinge, horizontal press (bench or push-up), vertical press (overhead), horizontal pull (row), and vertical pull (lat pulldown or pull-up). These patterns cover the entire musculature with six to eight movements and maximise the anabolic stimulus per unit of time.
        </p>

        <p>
          <strong>Volume:</strong> The evidence-based minimum for lean mass preservation during a caloric deficit is approximately 10 sets per muscle group per week, distributed across sessions. For a three-day full-body programme, this means roughly 3–4 working sets per major movement per session.
        </p>

        <p>
          <strong>Load:</strong> Hypertrophic stimulus occurs across a broad rep range — 6 to 30 repetitions per set, provided the set is taken close to failure (within 2–3 reps of the point where another rep would be impossible). The common misconception that only heavy weight (1–5 rep range) builds muscle is not supported by current evidence. What matters is proximity to failure and progressive overload over time.
        </p>

        <p>
          <strong>Progressive overload:</strong> The training stimulus must increase over time to continue driving adaptation. This can mean adding load, adding reps, adding sets, or reducing rest periods. Without progression, the body adapts to the existing stimulus and lean mass preservation becomes harder to sustain.
        </p>

        <hr />

        <h2>The Protein-Training Interaction: Getting the Nutrition Right</h2>

        <p>
          Resistance training without adequate protein is substantially less effective. The two interventions are synergistic — training creates the anabolic signal, protein provides the substrate to respond to it. Neither alone produces the body composition outcomes that both together achieve.
        </p>

        <p>
          On GLP-1 therapy, protein targeting requires deliberate attention because appetite suppression is significant. People who reduce total caloric intake from, say, 2,200 calories to 1,300 calories may inadvertently drop protein intake below the threshold needed to support lean mass, even if they're eating proportionally healthily.
        </p>

        <p>
          The target is <strong>1.6 grams of protein per kilogram of body weight per day</strong>, as a minimum. For a 90 kg person, that's 144 grams of protein daily. For a 75 kg person, 120 grams. These numbers sound large, but they're achievable with planning. Examples: 200g chicken breast (~44g protein), 200g Greek yoghurt (~20g protein), 200g cottage cheese (~24g protein), two eggs (~12g), one scoop whey protein supplement (~25g). Across three meals and a snack, reaching 120–150g is manageable.
        </p>

        <p>
          A practical strategy on GLP-1 therapy: <strong>protein first at every meal</strong>. When appetite is suppressed and you're eating significantly less total volume, filling that reduced capacity with protein before carbohydrates and fat ensures the macronutrient that matters most for lean mass isn't crowded out.
        </p>

        <hr />

        <h2>Practical Challenges: Nausea, Energy, and Timing</h2>

        <p>
          GLP-1 medications cause nausea, particularly in the early weeks and at dose escalation. Training on a queasy stomach is neither enjoyable nor productive. Practical modifications:
        </p>

        <p>
          <strong>Timing relative to injection:</strong> Semaglutide is injected once weekly; nausea typically peaks 24–72 hours post-injection. Schedule harder training sessions toward the end of the injection week, when nausea has subsided. Lighter sessions — body weight movements, mobility work — can be scheduled closer to injection day without significant GI risk.
        </p>

        <p>
          <strong>Pre-workout nutrition:</strong> Train in a slightly fed state — a small, protein-forward meal 1–2 hours before. A large meal before training will worsen nausea. Protein shakes tolerated well on an unsettled stomach by many people; solid food less reliably.
        </p>

        <p>
          <strong>Energy levels:</strong> Caloric restriction reduces available energy. Intensity-adjusted training — accepting that you may not lift as heavy or complete as much volume during an early phase of appetite suppression — is more sustainable than trying to maintain pre-diet performance levels and repeatedly failing. Progressive overload applies across months, not just sessions.
        </p>

        <p>
          <strong>Recovery:</strong> Sleep is the primary recovery modality. Chronically short sleep — less than 7 hours — impairs muscle protein synthesis and increases cortisol, which is catabolic. On a medically supervised weight loss programme, sleep quality deserves the same attention as training and nutrition.
        </p>

        <hr />

        <h2>What "Complete" Actually Means</h2>

        <div class="pull-quote">
          <p>"Resistance exercise should be standard co-prescription with GLP-1 therapy — not an optional add-on." — Cell Reports Medicine, 2025</p>
        </div>

        <p>
          A complete GLP-1 programme — one that produces durable fat loss, lean mass preservation, metabolic protection, and the best possible platform for weight maintenance after stopping — integrates three components that each do work the others cannot.
        </p>

        <p>
          <strong>The medication</strong> creates the caloric deficit by suppressing appetite through neurobiological mechanisms that willpower alone cannot reliably sustain. It does not know which tissue to spare.
        </p>

        <p>
          <strong>Resistance training</strong> provides the anabolic signal that tells the body to preserve muscle while losing fat. Without it, the medication-driven deficit will draw indiscriminately on available energy stores — including the lean mass you want to keep.
        </p>

        <p>
          <strong>Dietary protein</strong> provides the substrate for the anabolic signal to act on. Without adequate protein, the training stimulus cannot produce the protein synthesis needed to preserve muscle during the deficit.
        </p>

        <p>
          These three are a system, not a menu from which you choose one. The DXA evidence from STEP 1 tells us what happens with medication alone. The Longland and Morton data tell us what becomes possible when training and protein are added. The difference — between losing 39% lean mass versus preserving or gaining it — is not trivial. It is the difference between a body that's lighter and a body that's genuinely healthier.
        </p>

        <hr />

        <h2>The Physician's Summary</h2>

        <p>
          Resistance training on GLP-1 medication is not optional. The STEP 1 DXA data are clear: without it, a substantial proportion of weight lost comes from lean mass — the tissue that determines metabolic rate, functional capacity, and long-term weight maintenance. With it, combined with protein intake at 1.6 g/kg/day, the same caloric deficit can produce fat loss with muscle preservation or even gain.
        </p>

        <p>
          The minimum effective programme is three sessions per week of compound resistance training, taken close to failure, with progressive overload over time. Nausea and reduced energy during GLP-1 dose escalation can be managed with timing adjustments and realistic intensity expectations; they are not reasons to stop.
        </p>

        <p>
          Aristotle was right about habit. Not the heroic session you do once when motivated, but the three sessions a week you do consistently — when you're tired, when nausea is uncomfortable, when you'd rather not — those are what change the body. That's where the outcome lives.
        </p>

        <!-- ═══ Sources ═══════════════════════════════════════════════════ -->
        <div class="article-sources">
          <span class="sources-label">Sources</span>
          <p>Wilding JPH et al. "Once-weekly semaglutide in adults with overweight or obesity." <em>New England Journal of Medicine</em>, 2021 (STEP 1 trial, DXA sub-study, n=140).</p>
          <p>Longland TM, Oikawa SY, Mitchell CJ, Devries MC, Phillips SM. "Higher compared with lower dietary protein during an energy deficit combined with intense exercise promotes greater lean mass gain and fat mass loss: a randomized trial." <em>American Journal of Clinical Nutrition</em>, 2016;103(3):738–746.</p>
          <p>Morton RW, Murphy KT, McKellar SR, et al. "A systematic review, meta-analysis and meta-regression of the effect of protein supplementation on resistance training-induced gains in muscle mass and strength in healthy adults." <em>British Journal of Sports Medicine</em>, 2018;52:376–384.</p>
          <p>Cell Reports Medicine commentary. "Resistance exercise as co-prescription with GLP-1 therapy," 2025.</p>
        </div>

        <!-- ═══ Back Link ═════════════════════════════════════════════════ -->
        <a href="/blog.html" class="back-link">← Back to Articles</a>

      </div>
    </div>
  </main>

  <!-- ═══ Footer CTA ══════════════════════════════════════════════════════ -->
  <section class="footer-cta">
    <span class="label">Consultation</span>
    <h2>On GLP-1 Therapy? Build the Complete Programme.</h2>
    <p class="footer-cta__sub">
      A 45-minute consultation to design your resistance training protocol, set protein targets, and monitor body composition — so the weight you lose is fat, not muscle.
    </p>
    <a href="tel:+37252999399" class="btn btn--filled">Call +372 52 99939</a>
  </section>

  <!-- ═══ Footer Legal ════════════════════════════════════════════════════ -->
  <footer class="footer-legal">
    <div class="footer-legal__inner">
      <p>© 2026 Élan Clinic · Elan Clinic OÜ · Reg 17338832 · Medical licence L07470 · Sepapaja 12/1, Tallinn 11415</p>
      <p>This article is for informational purposes only and does not constitute medical advice. Consult your physician before changing any medication or health programme.</p>
    </div>
  </footer>

</body>
</html>
